NYSE · MMS
Industrials · Specialty Business Services
$58.18
Down-$0.57 (-0.98%)
Updated Sep 16, 2026, 9:16 PM
SID Score
4.6/10
Composite research score
Smart Money
58/100
Neutral
Price performance
1M range · 20 trading sessions · Daily adjusted prices
MMS closed at $58.18 after 20 trading sessions, up 3.17% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 15, 2026 | $58.46 | $59.10 | $57.86 | $58.18 | 754.75K |
| Sep 14, 2026 | $58.52 | $59.79 | $57.155 | $59.35 | 816.51K |
| Sep 11, 2026 | $56.67 | $57.42 | $55.965 | $56.92 | 453.67K |
| Sep 10, 2026 | $56.04 | $57.025 | $55.88 | $56.53 | 447.53K |
| Sep 9, 2026 | $56.42 | $56.66 | $55.34 | $56.11 | 824.69K |
| Sep 8, 2026 | $57.05 | $57.05 | $55.565 | $56.33 | 446.23K |
| Sep 4, 2026 | $57.52 | $57.9875 | $56.71 | $57.66 | 469.55K |
| Sep 3, 2026 | $58.00 | $59.19 | $57.375 | $58.43 | 442.61K |
| Sep 2, 2026 | $57.43 | $58.32 | $56.47 | $57.59 | 554.17K |
| Sep 1, 2026 | $57.76 | $58.66 | $57.60 | $57.64 | 524.05K |
| Aug 31, 2026 | $59.17 | $59.17 | $57.68 | $57.77 | 764.72K |
| Aug 28, 2026 | $59.70 | $60.69 | $59.51 | $59.75 | 373.45K |
| Aug 27, 2026 | $58.92 | $60.125 | $58.775 | $59.54 | 359.55K |
| Aug 26, 2026 | $58.15 | $59.265 | $57.82 | $58.97 | 364.4K |
| Aug 25, 2026 | $57.74 | $58.65 | $57.60 | $58.53 | 331.03K |
| Aug 24, 2026 | $58.20 | $58.71 | $58.01 | $58.24 | 345.86K |
| Aug 21, 2026 | $57.81 | $58.565 | $57.50 | $58.22 | 368.58K |
| Aug 20, 2026 | $58.08 | $58.68 | $57.44 | $57.76 | 439.17K |
| Aug 19, 2026 | $56.84 | $59.03 | $56.625 | $58.40 | 476.56K |
| Aug 18, 2026 | $55.10 | $57.00 | $55.10 | $56.39 | 565.38K |
The latest Smart Investors Daily articles mentioning MMS.
MMS research
Company profile and research snapshot.
Maximus Inc designs, develops, and delivers programs enabling people to access vital government services. It translates health and human services public policy into operating models that achieve outcomes for governments at scale. The company covers a broad array of services, including the operation of large health insurance eligibility and enrollment programs; clinical services, including assessments, appeals, and independent medical reviews; and technology services. The company operates through the following segments: U.S. Federal Services, U.S. Services, and Outside the U.S. A majority of its revenue is derived from the U.S. Federal Services segment, which engages with various U.S. federal government agencies to deliver clinical services, maintenance services, and technology solutions.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jan 2, 2025 | Raymond James | Outperform | — |
| Jan 3, 2024 | Raymond James | Market Perform | — |
| Aug 18, 2023 | Stifel | Buy | — |
| Feb 9, 2023 | Raymond James | Outperform | — |
| May 6, 2022 | Raymond James | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.
ChartMill · Sep 3, 2026
Discover why MAXIMUS (MMS) passes the Best Dividend screen with dependable payouts, solid profitability, and healthy financials for steady income.
Yahoo · Sep 1, 2026
Veralto gains from strong Water Quality and PQI demand, strategic buyouts and solid cash flow, while competition and a short public history pose risks.
Yahoo · Sep 1, 2026
Global bond yields are climbing as investors factor in higher inflation and tighter central bank policy, which has put pressure on many large, rate-sensitive stocks. That kind of backdrop can create pricing gaps in smaller, high quality US companies that big funds are not focused on. This article highlights three under followed stocks from a rigorous fundamental screener that may appeal to patient investors hunting for mispriced quality. The stocks profiled below are just a starting sample...
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning MMS.
